Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Joana Goncalves Biography and Net Worth

Insider of Cara Therapeutics

Dr. Goncalves brings more than 17 years of leadership experience in the biopharmaceutical industry to Cara. Most recently, she served as Vice President, Medical Affairs for Dermatology and Neurology at Celgene Corporation where she was instrumental in planning and executing medical support activities for a number of programs, including OTEZLA^® for psoriasis. Previously, Dr. Goncalves held the position of Vice President, Medical Strategy and Scientific Affairs at LEO Pharma Inc., the U.S. subsidiary of LEO Pharma A/S. She began her pharmaceutical career at Novartis Pharmaceuticals, working on a range of products across various therapeutic areas. Dr. Goncalves received her M.D. from the University of Cape Town, South Africa.

What is Joana Goncalves' net worth?: The estimated net worth of Joana Goncalves is at least $22,552.05 as of April 5th, 2024. Dr. Goncalves owns 53,365 shares of Cara Therapeutics stock worth more than $22,552 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Goncalves may own. Learn More about Joana Goncalves' net worth.
How do I contact Joana Goncalves?: The corporate mailing address for Dr. Goncalves and other Cara Therapeutics executives is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. Cara Therapeutics can also be reached via phone at (203) 406-3700 and via email at [email protected]. Learn More on Joana Goncalves' contact information.
Has Joana Goncalves been buying or selling shares of Cara Therapeutics?: Joana Goncalves has not been actively trading shares of Cara Therapeutics over the course of the past ninety days. Most recently, Joana Goncalves sold 2,753 shares of the business's stock in a transaction on Friday, April 5th. The shares were sold at an average price of $0.83, for a transaction totalling $2,284.99. Following the completion of the sale, the insider now directly owns 53,365 shares of the company's stock, valued at $44,292.95. Learn More on Joana Goncalves' trading history.
Who are Cara Therapeutics' active insiders?: Cara Therapeutics' insider roster includes Derek Chalmers (CEO), Joana Goncalves (Insider), Jeffrey Ives (Director), Frederique Menzaghi (SVP), Christopher Posner (President, CEO & Director), Thomas Reilly (CFO), Scott Terrillion (Insider), and Martin Vogelbaum (Director). Learn More on Cara Therapeutics' active insiders.
Are insiders buying or selling shares of Cara Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 60,503 shares worth more than $33,858.03. The most recent insider tranaction occured on May, 2nd when CEO Christopher Posner sold 3,936 shares worth more than $2,952.00. Insiders at Cara Therapeutics own 3.1% of the company. Learn More about insider trades at Cara Therapeutics.
Information on this page was last updated on 5/2/2024.

Joana Goncalves Insider Trading History at Cara Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/5/2024	Sell	2,753	$0.83	$2,284.99	53,365
1/17/2023	Sell	2,265	$10.81	$24,484.65	67,371
12/21/2022	Sell	2,992	$11.27	$33,719.84	71,901
11/1/2021	Sell	1,000	$17.15	$17,150.00
10/27/2021	Sell	1,000	$15.00	$15,000.00
4/21/2021	Sell	3,000	$27.63	$82,890.00	43,610
3/22/2021	Sell	3,000	$19.65	$58,950.00	30,610
1/21/2021	Sell	2,000	$20.12	$40,240.00	28,075
12/21/2020	Sell	2,000	$15.00	$30,000.00	27,373
11/23/2020	Sell	2,000	$15.31	$30,620.00	29,373
11/10/2020	Sell	2,000	$15.00	$30,000.00	31,373
10/20/2020	Sell	2,000	$15.00	$30,000.00	33,373
6/12/2020	Sell	10,627	$15.05	$159,936.35	46,000

Joana Goncalves Buying and Selling Activity at Cara Therapeutics

Cara Therapeutics Company Overview

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Today's Range

Now: $0.42

$0.34

$0.46

50 Day Range

MA: $0.29

$0.25

$0.42

2 Week Range

Now: $0.42

$0.23

$1.15

Volume

5,343,930 shs

Average Volume

858,401 shs

Market Capitalization

$23.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64